CliffBio
small molecule

GOZELLIX

GALLIUM GA-68 GOZETOTIDE

Loss of exclusivityJuly 2035latest FDA-listed patent expiry
CompanyTELIX INNOVATIONS SA

Drug detail

Brand nameGOZELLIX
Active ingredientGALLIUM GA-68 GOZETOTIDE
StrengthN/A
Dosage formPOWDER
RouteINTRAVENOUS
ModalitySmall molecule
FDA approvalMarch 2025
Marketing statusRX

Listed patents

PatentExpiresType
11027031July 2035use U-3317

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.